Uromems raised $60M in a growth round announced on May 15, 2026. UroMems is a medical device company developing smart active implantable technology to treat stress urinary incontinence in women and men.
UroMems is a medical device company developing smart active implantable technology to treat stress urinary incontinence in women and men.
Uromems, based in Grenoble, France, announced $60M in growth financing on May 15, 2026.
Participants include Ajax Health Fund I.
Swiss clinical-stage biotechnology company pioneering the development of next-generation copper-based radiopharmaceuticals for the diagnosis and treatment of cancer.